Nucs AI Launches TrackPSMA to Revolutionize Prostate Cancer Treatment

Nucs AI has unveiled TrackPSMA, a cutting-edge tool designed to enhance the assessment of treatment response in prostate cancer patients undergoing radioligand therapy. This innovative technology aims to address the significant challenge that more than half of these patients face: the risk of non-response to treatment. The launch, announced on November 25, 2025, in New York, positions Nucs AI at the forefront of AI-driven solutions in radiology.

Prostate cancer treatment continues to evolve, with radioligand therapy emerging as a leading modality. Yet, identifying the patients most likely to benefit from this treatment remains a pressing concern. Studies indicate that approximately 54% of patients might not respond to therapy, highlighting the necessity for tools that can quickly and effectively assess treatment efficacy. TrackPSMA aims to fill this gap, providing physicians with a quantitative approach to monitor patient responses and adjust treatment plans as necessary.

AI-Powered Insights for Improved Patient Care

TrackPSMA utilizes artificial intelligence to analyze PSMA-PET/CT scans, enabling healthcare professionals to evaluate treatment responses over time. This capability allows for early identification of disease progression, which is crucial for making timely decisions that could optimize patient care. The tool also facilitates lesion-by-lesion tracking, presenting a detailed view of changes in individual tumors and providing a standardized assessment that is typically unavailable in conventional evaluations.

Farid Yagubbayli, Chief Technology Officer at Nucs AI, emphasized the significance of this development, stating, “Being able to track disease progression lesion by lesion represents a fundamental shift in how experts understand and manage cancer over time.” He highlighted that TrackPSMA transforms subjective visual assessments into a standardized, data-driven process, allowing physicians to act with increased confidence and speed.

Nijat Ahmadov, the CEO of Nucs AI, further articulated the potential impact of TrackPSMA, noting, “By providing automated, standardized, and highly accurate treatment response assessments, we’re enabling better understanding of which treatment scenarios yield positive outcomes and where alternative strategies might be necessary.”

Streamlining Treatment and Enhancing Efficiency

The introduction of TrackPSMA complements Nucs AI’s existing solutions, including DeepPSMA and SelectPSMA, which have already demonstrated substantial benefits in reducing manual analysis and improving patient stratification for radioligand therapy. By streamlining workflows, Nucs AI not only helps alleviate the administrative burden on radiologists but also enhances accuracy, reduces burnout, and ultimately lowers healthcare costs.

This launch represents a crucial milestone in Nucs AI’s mission to reshape the landscape of medical imaging. The company has formed strategic partnerships with prestigious institutions, including Johns Hopkins, to further expand its portfolio in response to the growing demand for AI-powered radiology solutions.

As healthcare professionals strive for better outcomes in cancer treatment, TrackPSMA stands to redefine the standards for evaluating treatment responses in prostate cancer. Interested individuals can learn more by visiting Nucs AI’s booth at RSNA 2025, where the company will showcase how it is enhancing evidence-based response evaluation for next-generation radiopharmaceutical therapies.

For further information about Nucs AI and its innovative solutions, visit www.nucs.ai or contact [email protected]